74386-55-3

Upstream product

• 74386-59-7 5-benzyloxy-2-pyridinecarboxylic acid methyl ester 
• 63793-98-6 5-benzyloxy-2-methyl-pyridine 
• 59781-08-7 5-benzyloxypyridin-2-carbaldehyde 

Downstream Products

• 787564-19-6 2-[(5-benzyloxypyridine-2-carbonyl)amino]malonic acid dimethyl ester 
• 858602-75-2 5-benzyloxypyridine-2-carboxylic acid N-methoxy-N-methylamide 
• 1208536-57-5 C₁₅H₁₆N₂O₂ 
• 1208536-50-8 2-(azetidin-1-ylcarbonyl)-5-(benzyloxy)pyridine 
• 1208536-60-0 C₁₅H₁₆N₂O₂ 
• 362699-65-8 5-(benzyloxy)-N-{4-[2-(hydroxyamino)-2-oxoethyl]-4-piperidinyl}-2-pyridinecarboxamide trifluoroacetate 

Relevant academic research and scientific papers

OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE

The present invention relates to compounds, which are useful for treatment and/or prevention of diabetes mellitus, diabetes mellitus complications or obesity, since the compounds have glucokinase-activating effects, and are presented in Formula (I): wherein R1 represents a carbamoyl group; R2 represents a lower alkyl group; both of X1 and X2 represent CH, or any one of X1 and X2 represents a nitrogen atom and the other represents CH; a group of represents a group selected from the group consisting of a pyridinyl, a pyrazinyl, a pyrazolyl, a thiadiazolyl, a triazolyl, an isoxazolyl and a thiazolyl group; and k is zero or 1, or relates to pharmaceutically acceptable salts thereof.

IMIDAZOPYRIDINE COMPOUND

The present invention provides an imidazopyridine compound represented by formula (I), wherein R1 and R2 each independently represent a C1-6 alkyl group et al; R3 and R4 each independently represent a hydrogen atom, a methyl et al; Ar1 is a divalent substituent representing a monocyclic or bicyclic, 3- to 8-membered aromatic or aliphatic heterocyclic group et al; Ar2 represents an aromatic carbocyclic group, or an aromatic heterocyclic group; W represents -(CH2)m et al, and m indicates an integer of from 0 to 10. This compound acts as a melanin concentrating hormone receptor antagonist, and is useful as treating agents for obesity.

1,5-DIHETEROCYCLE-1H-TRIAZOLE DERIVATIVE

The present invention relates to a compound represented by Formula (I): wherein Ar1, Ar2, R1 and R2 each represent a substituent, a salt thereof, or a solvate of the compound or the salt, and to a medicine containing the same. According to the present invention, a potent platelet aggregation suppressant which does not inhibit COX-1 and COX-2 is provided.

FIVE-MEMBERED HETEROCYCLIC DERIVATIVE

The present invention relates to a compound represented by formula (I): a salt of the compound, or a solvate of the compound or the salt; a drug containing any of the compounds, the salts, and the solvates; a preventive and/or therapeutic agent for an ischemic disease containing any of the compounds, the salts, and the solvates; and a platelet coagulation inhibitor containing any of the compounds, the salts, and the solvates. The compound of the present invention is useful as a strong platelet coagulation inhibitor without inhibiting COX-1 or COX-2.

AMIDOPYRAZOLE DERIVATIVE

A platelet coagulation inhibitor which inhibits neither COX-1 nor COX-2 is provided. The inhibitor is a compound represented by general formula (I): wherein Ar1 and Ar2 independently represent a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents, or a phenyl group optionally substituted with 1 to 3 substituents; R1 represents a lower acyl group, carboxyl group, a lower alkoxycarbonyl group, a lower alkoxy group, a lower alkyl group optionally substituted with 1 or 2 substituents, a carbamoyl group optionally substituted with 1 or 2 substituents, an oxamoyl group optionally substituted with 1 or 2 substituents, an amino group optionally substituted with 1 or 2 substituents, a 4- to 7-membered alicyclic heterocyclic group optionally substituted with 1 or 2 substituents, a phenyl group optionally substituted with 1 to 3 substituents, or a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents; and R2 represents hydrogen atom, a halogeno group, or the like.

SELECTIVE ESTROGEN RECEPTOR MODULATORS

The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Ra and Rb are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R' represents 1 to 4 independent hydrogen atoms and the like; and R" represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.

2-Pyridinecarboxylic acids

5-Etherified 2-pyridinecarboxylic acids, e.g. those of the formula STR1 or functional derivatives thereof, are hypotensive agents.

2-Pyridinecarbonitrile compounds

5-Etherified 2-pyridinecarboxylic acids, e.g. those of the formula STR1 R = phenyl or (alkyl, alkoxy, halogeno, CF3, CN, CONH2 or NH2)-phenyl R' = H or carboxy X = O or S, m = 1-4 or functional derivative thereof, are hypotensive agents.